BUZZ-Aquestive Therapeutics falls as FDA flags issues with oral allergy drug

Reuters01-09
BUZZ-Aquestive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> falls as FDA flags issues with oral allergy drug

** Shares of drug developer Aquestive Therapeutics AQST.O fall 44% to $3.49 premarket

** Co says it received a letter from the U.S. FDA highlighting issues with its new allergy treatment, Anaphylm

** FDA raised concerns delaying talks on Anaphylm's labeling and marketing, per co

** AQST's Anaphylm is a dissolvable film with epinephrine for severe allergic reactions - AQST

** The FDA is expected to make a decision on Anaphylm by January 31, the scheduled action date

** Co says if approved, it would be first oral alternative to epinephrine auto-injectors

** As of last close, stock up ~81% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment